News

Toxic substances that enter via the nose or gut give rise to toxic protein clumps that eventually cause Parkinson’s disease, researchers propose. “In both the brain-first and body-first scenarios the [disease mechanism] arises in structures in the body closely connected to the outside world,” Ray Dorsey, MD, a professor…

Parkinson’s disease may change the way basic emotions — such as anger, disgust, fear, happiness, sadness, and surprise — are felt in the body, a study suggests, opening up new perspectives into the disease’s nonmotor symptoms and how they’re managed. “The results of our study raise many interesting questions…

After adding $47 million in new funding, Cerevance is planning to launch a Phase 3 clinical trial to test its oral molecule CVN424, designed to treat people with early-stage Parkinson’s disease without the side effects seen with other therapies, the company announced in a press release. That…

There appears to be no link between a unique pattern of the gut microbiome — the genetic material carried by all of the microorganisms, such as bacteria, living in the gut — and mild cognitive impairment in people with Parkinson’s disease, a study found. The study, “Gut microbiome…

Scientists exploring the potential of machine learning approaches in drug discovery for Parkinson’s disease and other neurodegenerative disorders — focusing on misfolded proteins that are the hallmark of such conditions — found that one such method identified compounds “two orders of magnitude more potent” than ones previously reported, per…

People who carry a specific mutation in the RAB32 gene have a higher risk of developing Parkinson’s disease, researchers at the University of Florida found. The mutation, called RAB32 Ser71Arg, was identified in 16 individual families from different ethnic groups and increased the activation of the LRRK2 protein, a…

The Parkinson’s Foundation has joined forces with Tasso — a U.S. company that offers a sample collection and logistics platform for clinical trials — to accelerate genetic research into the underpinnings of Parkinson’s disease. The collaboration will harness Tasso’s patient-friendly blood collection technology to acquire small blood…

Six months of daily tavapadon, as an oral add-on therapy to standard levodopa, significantly increased on time without troublesome dyskinesia, or involuntary body movements, in people in the late stages of Parkinson’s disease, according to top-line data from a Phase 3 study. Data from the trial, dubbed…

A three-week ketogenic diet, one low in carbohydrates and high in fat, supplemented with a specific type of fat — called medium chain triglycerides — showed no significant benefits in easing motor symptoms in a small group of people with Parkinson’s disease, a pilot trial has found. Whether this…

People with Parkinson’s disease who experience digestive issues or probable rapid eye movement (REM) sleep behavior disorder may be as much as twice as likely to develop symptoms of psychosis, a study found. Understanding what predicts early-onset psychosis in Parkinson’s can help doctors identify at-risk patients sooner, enabling them…